| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 127, 2253-2262, Copyright © 1990 by Endocrine Society
ARTICLES |
R Civitelli, YS Kim, SL Gunsten, A Fujimori, M Huskey, LV Avioli and KA Hruska
Division of Bone and Mineral Metabolism, Jewish Hospital, Washington University Medical Center, St. Louis, Missouri 63110.
1,25-dihydroxycholecalciferol (1,25(OH)2D3) rapidly affects calcium (Ca2+) transport in several cell systems, suggesting physiological actions independent of genomic activation. To test this hypothesis, we studied immediate to early effects (0.5-300 sec) of 1,25(OH)2D3 on cytosolic Ca2+ [Ca2+]i in single osteogenic sarcoma ROS 17/2.8 cells loaded with fura-2. An acute rise in [Ca2+]i was observed in 40% of the cells following addition of 1,25(OH)2D3, with a threshold concentration of 10(-11) M. In most cases, the [Ca2+]i rise was transient, with return to baseline within 1 min; less frequently a more prolonged effect was observed, with variable recovery times. 25- hydroxycholecalciferol (25(OH)D3) reproduced the effect of 1,25(OH)2D3 on [Ca2+]i, with equal potency and similar responses, whereas 24,25- dihydroxycholecalciferol, 1 alpha-hydroxycholecalciferol, and 22 oxa- 1,25(OH)2D3 were not effective. 1,25(OH)2D3 also increased [Ca2+]i in ROS 24/1 cells, which are defective of receptors for the vitamin D metabolites. At high doses (10(-8)-10(-7) M) of 1,25(OH)2D3 the [Ca2+]i rise in ROS 17/2.8 cells was due to both influx of extracellular Ca2+ and release of Ca2+ from intracellular stores, as the effect was only partially inhibited by Ca2(+)-channel blockade by nifedipine. At low doses (10(-9)-10(-10) M), the effect was entirely dependent on extracellular Ca2+. 1,25(OH)2D3 also increased the production of inositol 1,4,5 trisphosphate (Ins(1, 4, 5)P3) and diacylglycerol, at a threshold dose of 10(-9) M, indicating activation of phospholipase C (PLC). In two thirds of the cells studied, a second addition of 1,25(OH)2D3 within 5 min to cells prestimulated with equimolar doses of the vitamin D metabolite resulted in a [Ca2+]i transient of higher amplitude than the first, a phenomenon occurring at all doses of the hormone, and associated with production of Ins(1, 4, 5)P3. This response amplification was not produced by 25(OH)D3, and pretreatment with 1 alpha(OH)D3 did not significantly enhance 1,25(OH)2D3-induced production of Ins(1, 4, 5)P3. In conclusion, activation of the Ca2+ message system by vitamin D metabolites is a rapid, nongenomic effect; 1,25(OH)2D3 specifically activates both PLC and dihydropyridine- sensitive Ca2+ channels, and "primes" the cells to respond with an enhanced [Ca2+]i rise to a subsequent homologous stimulation; the presence of both the 1 alpha and 25 hydroxyl groups is necessary to express the full hormonal action of vitamin D on [Ca2+]i.
This article has been cited by other articles:
![]() |
J. J. Bergh, Y. Shao, E. Puente, R. L. Duncan, and M. C. Farach-Carson Osteoblast Ca2+ permeability and voltage-sensitive Ca2+ channel expression is temporally regulated by 1,25-dihydroxyvitamin D3 Am J Physiol Cell Physiol, March 1, 2006; 290(3): C822 - C831. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Bergh, Y. Xu, and M. C. Farach-Carson Osteoprotegerin Expression and Secretion Are Regulated by Calcium Influx through the L-Type Voltage-Sensitive Calcium Channel Endocrinology, January 1, 2004; 145(1): 426 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Erben, D. W. Soegiarto, K. Weber, U. Zeitz, M. Lieberherr, R. Gniadecki, G. Moller, J. Adamski, and R. Balling Deletion of Deoxyribonucleic Acid Binding Domain of the Vitamin D Receptor Abrogates Genomic and Nongenomic Functions of Vitamin D Mol. Endocrinol., July 1, 2002; 16(7): 1524 - 1537. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling Multiple Actions of Steroid Hormones---A Focus on Rapid, Nongenomic Effects Pharmacol. Rev., December 1, 2000; 52(4): 513 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Crescioli, M. Maggi, G. B. Vannelli, M. Luconi, R. Salerno, T. Barni, M. Gulisano, G. Forti, and M. Serio Effect of a Vitamin D3 Analogue on Keratinocyte Growth Factor-Induced Cell Proliferation in Benign Prostate Hyperplasia J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2576 - 2583. [Abstract] [Full Text] |
||||
![]() |
M. Kajikawa, H. Ishida, S. Fujimoto, E. Mukai, M. Nishimura, J. Fujita, Y. Tsuura, Y. Okamoto, A. W. Norman, and Y. Seino An Insulinotropic Effect of Vitamin D Analog with Increasing Intracellular Ca2+ Concentration in Pancreatic {beta}-Cells through Nongenomic Signal Transduction Endocrinology, October 1, 1999; 140(10): 4706 - 4712. [Abstract] [Full Text] |
||||
![]() |
J. B. Safran, W. T. Butler, and M. C. Farach-Carson Modulation of Osteopontin Post-translational State by 1,25-(OH)2-Vitamin D3. DEPENDENCE ON Ca2+ INFLUX J. Biol. Chem., November 6, 1998; 273(45): 29935 - 29941. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Takeshita, K. Imai, S. Kato, S. Kitano, and S. Hanazawa 1alpha ,25-Dehydroxyvitamin D3 Synergism toward Transforming Growth Factor-beta 1-induced AP-1 Transcriptional Activity in Mouse Osteoblastic Cells via Its Nuclear Receptor J. Biol. Chem., June 12, 1998; 273(24): 14738 - 14744. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Reich, T. N. McAllister, S. Gudi, and J. A. Frangos Activation of G Proteins Mediates Flow-Induced Prostaglandin E2 Production in Osteoblasts Endocrinology, March 1, 1997; 138(3): 1014 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Slater, M. B. Kelly, Frank. J. Taddeo, J. D. Larkin, M. D. Yeager, J. A. McLane, C. Ho, and C. D. Stubbs Direct Activation of Protein Kinase C by 1alpha,25-Dihydroxyvitamin D(3) J. Biol. Chem., March 24, 1995; 270(12): 6639 - 6643. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |